Why is Eli Lilly using non-GAAP financial measures in this report?

Eli Lilly uses non-GAAP measures, such as adjusted net income and adjusted earnings per share, to provide investors with a clearer view of the company's ongoing operational performance. These measures exclude specific, often volatile or one-time charges and gains that can significantly impact GAAP results, making it easier for investors to compare performance across periods and identify underlying business trends.

What financial outlook did Lilly provide for 2005?

Eli Lilly provided financial expectations for both the first quarter and the full year of 2005. These projections were presented on both a GAAP basis and an adjusted basis, reflecting the company's strategy of offering insights into core performance while acknowledging potential impacts from specific charges or accounting changes.

How does the adoption of new accounting standards for share-based payments affect the reported results?

Effective January 1, 2005, Lilly adopted new accounting standards for share-based payments. To allow for a more meaningful year-over-year comparison with 2004, the company provided 'adjusted pro-forma earnings per share' for 2004, which assumes these new stock option expensing rules were applied in 2004 as well.

LLY 8-K: Earnings & Results

Q: What were the main reasons for the differences between GAAP and adjusted earnings in 2004?

The differences primarily stem from several significant charges incurred during 2004 and prior periods, including asset impairments, restructuring costs, tax expenses related to the repatriation of overseas earnings under the American Jobs Creation Act of 2004, and charges for acquired in-process research and development. A gain on the sale of patents in late 2003 was also an adjustment factor.

Summary

Eli Lilly & Company (LLY) filed an 8-K on January 26, 2005, to report its financial results for the fourth quarter and full year ended December 31, 2004. The filing primarily consists of a press release announcing these results, alongside financial statements. A key aspect highlighted is Lilly's use of non-GAAP financial measures, such as adjusted net income and diluted earnings per share, to provide a clearer view of its ongoing operations. The company detailed significant charges impacting its GAAP results in 2004, including asset impairments, restructuring charges, tax expenses related to the repatriation of overseas earnings under the American Jobs Creation Act of 2004, and charges for acquired in-process research and development. These non-GAAP adjustments are intended to offer investors a more comparable view of performance over time, excluding volatile or one-time items. Lilly also provided financial expectations for the first quarter and full year 2005, presenting guidance on both a GAAP and adjusted basis.

Key Highlights

1Eli Lilly announced its Q4 and full-year 2004 financial results via an 8-K filing on January 26, 2005.
2The company utilizes non-GAAP financial measures (adjusted net income, adjusted EPS) to present core operational performance, excluding specific charges.
3Significant charges impacting 2004 GAAP results include asset impairments, restructuring costs, and tax expense on overseas earnings repatriation.
4Charges for acquired in-process R&D related to the in-license of an insomnia compound from Merck KGaA and the acquisition of Applied Molecular Evolution were also noted.
5A gain on the sale of dapoxetine patents in Q4 2003 was also mentioned as an adjustment point for historical comparisons.
6Lilly provided forward-looking financial expectations for Q1 and full-year 2005 on both GAAP and adjusted bases.
7The company adopted new accounting standards for share-based payments effective January 1, 2005, and provided adjusted pro-forma EPS for 2004 to ensure comparable year-over-year analysis.

ELI LILLY & Co 8-K Report, Financial Results (Jan 26, 2005)

Summary

Key Highlights

Frequently Asked Questions